Analyst Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical and keeping the price target at $56.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Serge Belanger has given his Buy rating due to a combination of factors, including confidence in Collegium’s leadership and its execution strategy outlined during the recent Needham healthcare event. He appears encouraged by management’s strategic focus, operational discipline, and the company’s ability to communicate a clear roadmap for continued growth and value creation.
In addition, Belanger likely views the current valuation as attractive relative to Collegium’s fundamentals and long‑term prospects, making the risk‑reward profile compelling. His Buy rating reflects the expectation that the company can effectively capitalize on its market opportunities and that management’s plans, as discussed at the conference, support upside potential for COLL shares.